Mathew Martoma, 39, will be sentenced on the scheduled date of September 8 after US District Judge Paul Gardephe denied his motion for a judgement of acquittal and alternatively for a new trial.
Martoma was convicted in February for his role as the "central figure" in one of the most lucrative insider trading schemes in US history.
Bharara has also asked the court to order Martoma to forfeit his 2008 bonus totalling USD 9.4 million and pay a separate fine to reflect the "serious offense" committed by him.
In rejecting Martoma's motion to throw out his insider trading conviction, Gardephe said Martoma offered no persuasive argument in the trial against the "overwhelming circumstantial evidence" demonstrating that he traded on the securities of pharma companies Elan and Wyeth for his hedge fund SAC Capital after receiving confidential information from two doctors about an Alzheimer's disease drug trial.
"The assertion that there are no victims of Martoma's crimes is as astounding as it is meritless," the judge said.
The judge ruled that evidence at trial was sufficient to demonstrate that Martoma knew that he had received material, non-public information from the two doctors in violation of their duties to Elan and Wyeth.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
